白天上班久坐8小时，脖子僵、肩膀酸、腰直不起来，怎么坐都不舒服。 你以为自己只是累了，实际上是身体在"报警"！ 父母长辈上了年纪更是如此，换天气就跟着疼，膝盖不敢弯，胳膊抬不起来，晚上一翻身就 被"疼"醒。 不是老了，也不是矫情，而是这些小问题，真的拖不得、忍不得！ 贴敷后温热感渐起，随着皮肤温和升温，草本能量借浅表吸收，疲乏紧绷感都释放了！ 好在今天，这些困扰终于找到了缓解办法。 精选道地药材， 严循古法炮制，复刻百年匠心工艺！ 创办于1424年，600余年老品牌历史传承！线下 25w+药店有售 ！ 它就是传承600年的 —— 永安虎标活络贴 ✅一贴温热入骨，哪里不通贴哪里 ✅草本成分深层渗透，持久舒缓放松 ✅温感持续深入，就像做艾灸一样舒适 这款永安虎标活络贴，严循古方，无多余化学添加， 草本精粹深层舒缓。 刚贴上是满满的清凉感，稍作停留，肌肤便觉舒缓、放松。 通过专业品质检测，永安虎标活络贴严选天然药材，成分安全无刺激，可以安全放心使用。 多部位适用！59元到手一盒体验装，更有买二送一，买三送二超值周期装！ 分享个小惊喜，睡前贴在腰背部，舒缓肌肉紧绷的同时，整个人都放松下来，睡得格外安稳～ 道 地药材配 ...

在公益健康传播领域，医院以"中医药文化传播与普及，中医药健康进万家"为己任，积极践行社会责任。2023年度便组织大型"四送四进四提升"中医健康 义诊活动200余场，组建德技双馨的"老中青"中医药专家团队深入基层，提供免费诊疗服务，对确需用药的患者，可通过互联网医院便捷购药并享受药品 免费邮寄服务。2025年，医院持续推进"健康进万家"公益行动，走进各大企事业单位开展义诊活动，为职场人提供体质筛查、个性化调理方案、特色中医 疗法体验等服务，通过中医文化展、养生知识宣讲等形式，让"简、便、验、廉"的中医魅力触达更多人群。 山东新中鲁中医医院院长李树沛表示，此次荣获年度责任机构荣誉，是行业与社会对医院工作的高度认可，更是一份沉甸甸的责任。未来，医院将以此为 契机，继续坚守中医药核心价值观，深化中医药传承创新，持续提升医疗服务品质，拓展公益健康服务边界，积极响应2026"壹点问医"全民健康守护系列 行动号召，以"线上科普+线下服务"的联动模式，为群众提供更便捷、优质的中医药健康服务，为推进健康山东建设、推动中医药事业高质量发展注入更 多中医动能。山东新中鲁中医医院将以荣誉为灯塔，以责任为指引，在中医药守护民生健康（3 ...

据介绍，华润江中推出的六味地黄膏延续了传统膏滋形态，同时采用独立条状包装，携带与服用更为便 捷。这一"口袋化、轻养生"的设计，在随时随地满足养生需求的同时，也注重口感体验，产品中添加蜂 蜜，入口味甜微酸。 12月25日，华润江中旗下六味地黄膏在阿里健康首发。 据悉，该产品是对经典名方"六味地黄丸"的剂型革新，由传统丸剂转变为膏剂形态，独立条状包装，可 开袋即饮或温水冲服，旨在精准契合当代职场人群快节奏、场景化的日常调理需求。 行业数据显示，补肾类中成药市场规模持续增长，显示出消费惯性。据中国中药协会数据，2024年全国 补肾类中成药市场规模达487.3亿元，同比增长9.2%，占整体中成药市场的12.6%。市场增长背后是消费 场景与习惯的深刻变迁，快节奏的都市生活导致的疲劳、精力下降等问题在年轻职场人群中凸显，他们 对健康产品的需求转向高效、便捷与体验友好。 华润江中相关负责人表示："此次剂型创新，是江中践行'家中常备药'理念、满足现代人便捷健康需求 的具体体现，也展现了作为'中医药传承与创新引领者'的使命担当。我们希望通过更便利的形态，让经 典方剂更好地融入现代生活，服务于大众的健康调理。" 阿里健康方面对记 ...

11月27日至29日，三生（中国）2025年度盛典暨新品发布会在宁波奥体中心隆重举行。本次盛典以"梦 工厂，链万家"为主题，不仅是对三生21年辉煌历程的礼赞，更是对未来健康科技蓝图的全新擘画。 作为三生旗下承载中医药文化传承重任的核心品牌，御坊堂在本次盛典上完成了里程碑式的品牌升级与 创新——重磅发布"御坊堂AI慧诊仪"与"御坊堂大师膏方"系列新品，并宣布"本草驿站"公益项目正式落 地。这一系列举措标志着御坊堂正通过"中医药传承"与"科技创新"的双引擎驱动，致力于让传统养生智 慧更懂现代人，让健康管理方案真正落地万家。 数智引擎：AI慧诊仪重构中医健康管理新范式 三生深耕大健康产业20余年，始终在思考如何用更极致的产品和服务，去回应每一个时代对于健康的渴 望。在数字化浪潮席卷全球的今天，如何让传统中医的"望闻问切"突破时空限制服务更多人群，为每一 个家庭提供触手可及的个性化健康解决方案，是行业面临的一大痛点。三生给出的破局之道，正是以数 智化为桥梁，让传统养生与现代需求精准对接。 匠心传承：大师膏方演绎"药食同源"新高度 如果说AI慧诊仪代表了御坊堂在科技维度的探索高度，那么本次发布的"御坊堂大师膏方"系列， ...

Core Insights - Jiangzhong Pharmaceutical has established itself as a leader in the traditional Chinese medicine (TCM) sector, particularly with its flagship product, Jiangzhong Gastrointestinal Tablets, which has achieved over 10 billion yuan in annual sales and has sold more than 5 billion boxes over 30 years [1][5]. Group 1: Business Performance - Jiangzhong Gastrointestinal Tablets has maintained its position as the top-selling TCM digestive product in China for 21 consecutive years, reflecting strong brand loyalty and market presence [1]. - The company has reported a compound annual growth rate (CAGR) of 16% in revenue and 13% in net profit during the 14th Five-Year Plan period [1]. Group 2: Technological Innovation - The Jiangzhong Bay manufacturing base features an intelligent production line that automates the entire process from raw material handling to packaging, significantly reducing labor requirements from 200 to just over 10 personnel in liquid formulation [2][3]. - The company has achieved over 95% automation in its TCM extraction and production processes, marking a significant shift from traditional methods to smart manufacturing [3]. Group 3: Product Development - Jiangzhong Pharmaceutical has innovated traditional formulas, such as the "Shengmai San," by integrating modern ingredients to create products like "Huangqi Shengmai Drink," enhancing their appeal and efficacy [4]. - The company has focused on improving the taste and palatability of its products, such as the Jiangzhong Gastrointestinal Tablets, through advanced flavor masking and purification techniques [5]. Group 4: Cultural Integration - The company has launched initiatives like the "Jiangzhong Night Consumption Season," which creatively combines TCM ingredients with popular food trends, such as a digestive hot pot that incorporates elements from Jiangzhong Gastrointestinal Tablets [6]. - Jiangzhong Pharmaceutical aims to enhance the public's understanding and appreciation of TCM through cultural exhibitions and immersive experiences, thereby promoting the integration of traditional medicine into modern lifestyles [7].

Group 1: Jiangzhong Pharmaceutical - Jiangzhong Pharmaceutical's flagship product, Jianwei Digestive Tablets, has achieved cumulative sales of over 5 billion boxes and has been the top-selling OTC digestive medicine in China for 21 consecutive years [20][21] - The company aims to enhance quality through innovation, focusing on three main business areas: OTC products, health consumer goods, and prescription drugs, achieving a compound annual growth rate (CAGR) of 16% in revenue and 13% in net profit during the 14th Five-Year Plan period [20][21] - The company has implemented smart manufacturing technologies, achieving over 95% automation in its production processes, significantly improving efficiency and reducing labor costs [22][23] Group 2: Technological Innovation - Jiangzhong Pharmaceutical has developed a unique MVR concentration technology that enhances the extraction efficiency of active ingredients from traditional Chinese medicine to over 90% [22] - The company has established a national key laboratory for modern Chinese medicine creation, focusing on the innovative transformation of classic formulas into modern products [24] - The introduction of innovative flavors and purification techniques has transformed traditional herbal medicines into more palatable products, appealing to a broader consumer base [25] Group 3: Cultural Integration and Market Expansion - Jiangzhong Pharmaceutical has launched a "Healthy Hot Pot" concept that incorporates traditional medicinal ingredients, aiming to modernize and popularize traditional Chinese medicine among younger consumers [26][27] - The company plans to continue expanding its cultural outreach and application of traditional Chinese medicine through various channels, including tourism and dining [27] Group 4: Fushite Company - Fushite has positioned itself in the hydraulic pipeline sector, with a strategic focus on the mining after-market, anticipating a market size of $19.33 billion by 2030 [28][30] - The company has established a comprehensive service system that includes industrial maintenance and heavy spare parts supply, expanding its service capabilities beyond just hydraulic pipeline repairs [32] Group 5: Naipu Mining Machinery - Naipu Mining Machinery has developed a global service network covering over 50 countries, focusing on wear-resistant materials and mining machinery [34][36] - The company has successfully transitioned from basic spare parts production to advanced wear-resistant materials, leveraging new material technologies to enhance product performance [35][36] - Naipu's international strategy includes establishing production bases in Peru to meet the growing demand for mining equipment and spare parts in South America [39][40] Group 6: Sanxin Medical - Sanxin Medical has transformed from a traditional infusion and injection company to a significant player in the blood purification medical device sector, achieving a CAGR of 29.82% in net profit over the past five years [42][45] - The company has expanded its product offerings in blood purification, with revenue from this segment increasing from 20% in 2015 to 81% in 2024 [45] - Sanxin Medical is actively pursuing global market expansion, with overseas revenue growing by 39.70% in 2024, indicating a strong international presence [48][49]

Core Viewpoint - Tong Ren Tang has maintained steady growth in its performance despite external pressures and industry cycle adjustments, as evidenced by its Q3 2025 financial results [1] Financial Performance - In Q3 2025, Tong Ren Tang achieved operating revenue of 3.539 billion yuan, with a total operating revenue of 13.308 billion yuan for the first three quarters [1] - The net profit attributable to shareholders in Q3 was 232 million yuan, totaling 1.178 billion yuan for the first three quarters [1] - The company's steady performance is attributed to its "quality improvement and efficiency enhancement" strategy [1] Strategic Focus - The company has launched the "Quality Improvement and Efficiency Enhancement Return" action plan for 2025, focusing on core business and high-quality development [2] - Tong Ren Tang aims to strengthen its core competitiveness through deep collaboration across the entire supply chain, including R&D, procurement, production, and sales [2] Product and Brand Strength - Tong Ren Tang has developed a strong product portfolio, with over 400 traditional Chinese medicine products covering various therapeutic areas [3] - The company has established a complete industrial chain, including cultivation, processing, R&D, logistics, and retail, enhancing its brand and operational stability [3] Innovation and R&D - The company plans to increase its investment in R&D, with expenditures reaching 143 million yuan in the first three quarters, significantly higher than the previous year [5] - Future R&D efforts will focus on new drug development and improving existing products, including clinical studies for several key products [4] Brand Legacy and Future Outlook - Founded in 1669, Tong Ren Tang has a rich history and strong brand recognition in the traditional Chinese medicine sector, which supports its market competitiveness [6] - The company aims to enhance its brand influence and market dynamics through innovation, digital transformation, and international expansion [6][7]

Core Viewpoint - The second Maritime Silk Road Traditional Chinese Medicine Culture Forum was held in Zhangzhou, Fujian, focusing on the modern research value of Pianzaihuang, a traditional Chinese medicine product with a long clinical application history and significant efficacy [1][2] Group 1: Event Overview - The forum was themed "Maritime Silk Road Heritage, Zhang Medicine Flourishing" and featured the attendance of prominent figures such as Chinese Academy of Sciences academician and renowned TCM master Chen Keji [1] - The event included the release of the book "New Advances in Basic Research and Clinical Application of Pianzaihuang," edited by Chen Keji, which compiles major research findings since 2017 [1] Group 2: Research and Clinical Applications - The book details the historical development, TCM theories, main ingredients, production techniques, modern clinical applications, and quality control systems of Pianzaihuang [1] - It discusses the efficacy mechanisms of Pianzaihuang in treating liver diseases, tumors, inflammation, and immune regulation, providing a comprehensive overview of its academic achievements [1] Group 3: Contributions to Traditional Chinese Medicine - The research and clinical practice of Pianzaihuang demonstrate significant efficacy against diseases such as acute and chronic hepatitis, liver fibrosis, and primary liver cancer [2] - Pianzaihuang showcases the unique advantages of traditional Chinese medicine in disease prevention and treatment, emphasizing its role in the development of the national medicine industry and brand [2]

Core Points - The "Second Academic Conference on the Inheritance and Application of Zhang Zhongjing's Academic Thought" was held in Nanyang, Henan, attracting over 600 participants from the traditional Chinese medicine (TCM) field [1][2] - The conference emphasized the theme of inheriting Zhang Zhongjing's academic thought, promoting the culture of the medical sage, and advancing the development of new TCM [1] - Good Doctor Pharmaceutical Group plans to establish a TCM industry base that integrates research, clinical practice, and talent cultivation, aiming to benefit more patients [1] Group 1 - The conference featured activities such as the "Infertility and Reproductive Health Expert Tour" and the "Nodule and Tumor Prevention Expert Tour," along with the issuance of expert appointment letters and the presentation of "Zhang Zhongjing's Complete Works" [2] - Good Doctor Pharmaceutical Group's Vice General Manager expressed optimism about the future of TCM and highlighted the importance of understanding TCM culture [2] - The successful hosting of the event marks a new phase in the inheritance and application of Zhang Zhongjing's academic thought, indicating a collaborative and innovative approach to the future development of TCM [2]

Core Viewpoint - Jiangzhong Pharmaceutical Co., Ltd. reported a net profit of 522.34 million yuan for the first half of 2025, reflecting a year-on-year increase of 5.80% despite a decline in revenue [2][3][9] Financial Performance - Total revenue for the first half of 2025 was 2.14 billion yuan, down 5.79% from the previous year [2][3] - The total profit for the period was 703.24 million yuan, an increase of 12.01% compared to the same period last year [2][3] - The company's net assets reached 3.95 billion yuan, up 2.15% year-on-year [3] Business Segments - The OTC (over-the-counter) segment saw a revenue decline of 10.14%, attributed to changes in terminal demand [14] - The health consumer products segment achieved a revenue growth of 17.35%, focusing on self-researched products [14] - The prescription drug segment reported a revenue increase of 7.44%, emphasizing compliance and academic marketing [15] Industry Context - The pharmaceutical manufacturing industry experienced a PPI decline of 1.5% in the first half of 2025, with total revenue down 1.2% year-on-year [4][5] - National policies are aimed at enhancing medical insurance coverage and promoting high-quality development in the pharmaceutical sector [5][6] - The government is focusing on the development of traditional Chinese medicine, with initiatives to improve quality and promote innovation [8] Strategic Initiatives - The company is committed to brand-driven and innovation-driven growth, with plans to enhance its product matrix in key categories [18] - Jiangzhong Pharmaceutical is actively pursuing mergers and acquisitions to expand its product offerings and market presence [18] - The company is investing in digital transformation and smart manufacturing to improve operational efficiency and product quality [16][17]